[{"id":"afbd47be-ee4c-45b1-8494-95828143b693","acronym":"","url":"https://clinicaltrials.gov/study/NCT02743351","created_at":"2021-01-18T13:26:19.484Z","updated_at":"2024-07-02T16:35:56.309Z","phase":"Phase 1/2","brief_title":"Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies","source_id_and_acronym":"NCT02743351","lead_sponsor":"Fate Therapeutics","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • ProTmune (FT1050+FT4145 programmed mPB)"],"overall_status":"Completed","enrollment":" Enrollment 96","initiation":"Initiation: 12/20/2016","start_date":" 12/20/2016","primary_txt":" Primary completion: 12/04/2020","primary_completion_date":" 12/04/2020","study_txt":" Completion: 11/05/2021","study_completion_date":" 11/05/2021","last_update_posted":"2023-02-07"}]